Raspotnig Margrethe, Haugen Mette, Thorsteinsdottir Maria, Stefansson Ingunn, Salvesen Helga B, Storstein Anette, Vedeler Christian A
Department of Clinical Medicine, University of Bergen, Jonas Lies veg 87, 5021, Bergen, Norway.
Department of Neurology, Haukeland University Hospital, Jonas Lies veg 65, 5021, Bergen, Norway.
Cancer Immunol Immunother. 2017 Nov;66(11):1463-1471. doi: 10.1007/s00262-017-2041-8. Epub 2017 Jul 14.
Cerebellar degeneration-related protein 2 (CDR2) has been presumed to be the main antigen for the onconeural antibody Yo, which is strongly associated with ovarian cancer and paraneoplastic cerebellar degeneration (PCD). Recent data show that Yo antibodies also target the CDR2-like protein (CDR2L). We, therefore, examined the expression of CDR2 and CDR2L in ovarian cancer tissue from patients with and without Yo antibodies and from various other cancerous and normal human tissues.
Ovarian cancer tissue and serum samples from 16 patients were included in the study (four with anti-Yo and PCD, two with anti-Yo without PCD, five with only CDR2L antibodies, and five without onconeural antibodies). Clinical data were available for all patients. The human tissues were examined by western blot and immunohistochemistry using rabbit CDR2 and CDR2L antibodies.
Ovarian cancers from all 16 patients expressed CDR2 and CDR2L proteins. Both proteins were also present in normal and cancer tissue from mammary tissue, kidney, ovary, prostate, and testis.
CDR2L is present in ovarian cancers from patients with and without Yo antibodies as was shown previously for CDR2. In addition, both CDR2 and CDR2L proteins are more widely expressed than previously thought, both in normal and cancerous tissues.
小脑变性相关蛋白2(CDR2)被认为是肿瘤神经抗体Yo的主要抗原,该抗体与卵巢癌和副肿瘤性小脑变性(PCD)密切相关。最近的数据显示,Yo抗体也靶向CDR2样蛋白(CDR2L)。因此,我们检测了有或没有Yo抗体的卵巢癌患者的癌组织以及其他各种癌组织和正常人体组织中CDR2和CDR2L的表达。
本研究纳入了16例患者的卵巢癌组织和血清样本(4例有抗Yo抗体且患有PCD,2例有抗Yo抗体但无PCD,5例仅有CDR2L抗体,5例无肿瘤神经抗体)。所有患者均有临床资料。使用兔CDR2和CDR2L抗体通过蛋白质印迹法和免疫组织化学法检测人体组织。
16例患者的所有卵巢癌均表达CDR2和CDR2L蛋白。这两种蛋白也存在于乳腺组织、肾脏、卵巢、前列腺和睾丸的正常组织和癌组织中。
如先前对CDR2的研究所示,CDR2L存在于有或没有Yo抗体的卵巢癌患者中。此外,CDR2和CDR2L蛋白在正常组织和癌组织中的表达比先前认为的更广泛。